La Salvia, AnnaLens Pardo, AlbertoLópez López, ÁngelCarretero Puche, CarlosCapdevila, JaumeBenavent, MartaJiménez Fonseca, PaulaCastellano, DanielAlonso, TeresaTeule, AlexandreCustodio, AnaTafuto, SalvatoreLa Casta, AdelaidaSpada, FrancescaLópez Gonzálvez, AngelesGil Calderón, BeatrizEspinosa Olarte, PaulaBarbas, CoralGarcía Carbonero, RocíoSoldevilla Navarro, Beatriz2025-06-022025-06-022024-01-01La Salvia, A., Lens-Pardo, A., López-López, A., Carretero-Puche, C., Capdevila, J., Benavent, M., Jiménez-Fonseca, P., Castellano, D., Alonso, T., Teule, A., Custodio, A., Tafuto, S., La Casta, A., Spada, F., Lopez-Gonzalvez, A., Gil-Calderon, B., Espinosa-Olarte, P., Barbas, C., Garcia-Carbonero, R., & Soldevilla, B. (2024). Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survival. European Journal of Endocrinology, 190(1), 62-74. https://doi.org/10.1093/EJENDO/LVAD1600804-464310.1093/ejendo/lvad160https://hdl.handle.net/20.500.14352/120738This work was partially funded by Pfizer, Project G1808 from the Grupo Español de Tumores Neuroendocrinos (GETNE), Ministerio Ciencia e Innovación (Spain) Spain (MICINN) and FEDER funding (Ref. RTI2018-095166-B-I00), and Comunidad Autónoma de Madrid (NOVELREN-CM. Ref: B2017/BMD3751). A.L.S. was funded by Instituto de Salud Carlos III (ISCIII) (Contrato Rio Hortega). A.L.-P. is funded by Comunidad Autónoma de Madrid (PEJD-2019-PRE/BMD-17058, Progama de Empleo Juvenil (YEI)), co-funded by European Union (ERDF/ESF, “Investing in your future”). C.C.-P. was partially funded by CAM (PEJD-2016-PRE/BMD-2666). B.R.-C. was partially funded by CAM (PEJD-2017-PRE/BMD-4981). B.S. was funded by Asociación Española Contra el Cáncer (AECC) (POSTDO46SOLD, Spain).Objective. Metabolic profiling is a valuable tool to characterize tumor biology but remains largely unexplored in neuroendocrine tumors (NETs). Our aim was to comprehensively assess the metabolomic profile of NETs and identify novel prognostic biomarkers and dysregulated molecular pathways. Design and Methods. Multiplatform untargeted metabolomic profiling (GC-MS, CE-MS, and LC-MS) was performed in plasma from 77 patients with G1-2 extra-pancreatic NETs enrolled in the AXINET trial (NCT01744249) (study cohort) and from 68 non-cancer individuals (control). The prognostic value of each differential metabolite (n = 155) in NET patients (P < .05) was analyzed by univariate and multivariate analyses adjusted for multiple testing and other confounding factors. Related pathways were explored by Metabolite Set Enrichment Analysis (MSEA) and Metabolite Pathway Analysis (MPA). Results. Thirty-four metabolites were significantly associated with progression-free survival (PFS) (n = 16) and/or overall survival (OS) (n = 27). Thirteen metabolites remained significant independent prognostic factors in multivariate analysis, 3 of them with a significant impact on both PFS and OS. Unsupervised clustering of these 3 metabolites stratified patients in 3 distinct prognostic groups (1-year PFS of 71.1%, 47.7%, and 15.4% (P = .012); 5-year OS of 69.7%, 32.5%, and 27.7% (P = .003), respectively). The MSEA and MPA of the 13-metablolite signature identified methionine, porphyrin, and tryptophan metabolisms as the 3 most relevant dysregulated pathways associated with the prognosis of NETs. Conclusions. We identified a metabolomic signature that improves prognostic stratification of NET patients beyond classical prognostic factors for clinical decisions. The enriched metabolic pathways identified reveal novel tumor vulnerabilities that may foster the development of new therapeutic strategies for these patients.engAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/journal article1479-683Xhttps://doi.org/10.1093/ejendo/lvad16038033321https://academic.oup.com/ejendo/article/190/1/62/7456030?login=true#435133984open access616.4616-006.04612.015.3612.8MetabolomicsNeuroendocrine tumorsPlasma metabolitesPrognostic biomarkerEndocrinologíaOncologíaFisiología3205.02 Endocrinología3207.13 Oncología2411 Fisiología Humana2411.08 Metabolismo Humano2411.12 Fisiología del Sistema Nervioso Central